The Virginia Life Sciences Imperative: Modernizing the Research and Development Tax Credit for the Era of Regenerative Medicine

1. Introduction

The Commonwealth of Virginia stands at a critical juncture in its pursuit of global leadership within the life sciences sector. As the global biotechnology market is forecast to reach over $5 trillion by 2034, the competitive landscape for attracting and retaining high-growth startups is increasingly defined by the sophistication and inclusivity of state-level research and development incentives. For over a decade, Virginia has utilized its Research and Development (R&D) tax credit framework to anchor an innovation ecosystem that spans from the pharmaceutical manufacturing clusters in the Greater Richmond-Petersburg region to the cutting-edge biomedical research corridors of Charlottesville, Roanoke, and Blacksburg. However, the existing statutory framework contains a specific exclusionary provision that prohibits taxpayers from claiming credits for research conducted on human cells or tissue derived from induced abortions or from stem cells obtained from human embryos. While originally intended to address ethical concerns, this exclusion now functions as a significant regulatory and financial barrier for a specialized but vital subset of biotechnology small to medium-sized businesses (SMBs) that are foundational to the future of regenerative medicine.

This whitepaper provides an exhaustive analysis of the Virginia R&D tax credit infrastructure, contextualizes the bio-medical research exclusion within the broader scientific and economic landscape, and proposes two practical, state-level solutions to reform this policy. By aligning Virginia’s tax incentives with established federal ethical registries and creating specialized tiers for life science innovation, the Commonwealth can catalyze a new era of medical breakthroughs, ensure the retention of elite scientific talent, and generate a long-term return on investment that far exceeds the initial fiscal outlay.

2. The Architecture of Innovation: Virginia’s R&D Tax Credit Framework

Virginia’s support for research and development is codified primarily through two distinct but related tax credits: the Research and Development Expenses Tax Credit (Standard R&D Credit) and the Major Research and Development Expenses Tax Credit (Major R&D Credit). Together, these programs form the financial backbone for the Commonwealth’s innovation economy, yet both are currently facing an uncertain future due to legislative sunset provisions and the existing bio-medical exclusions.

The Standard Research and Development Expenses Tax Credit (§ 58.1-439.12:08)

The Standard R&D Credit is designed to support the research activities of small to medium-sized businesses, defined generally as those with less than $5 million in annual Virginia qualified research and development expenses (QREs). This credit is perhaps the most significant tool for early-stage startups, as its refundability provides immediate cash flow to companies that have not yet reached profitability. For taxable years beginning on or after January 1, 2021, but before January 1, 2025, the credit was structured to offer 15 percent of the first $300,000 in Virginia QREs, or 20 percent if the research was conducted in conjunction with a Virginia public or private institution of higher education.

Table 1: Standard R&D Credit Specifications

The refundability of this credit is a critical mechanism for the “pre-revenue” biotechnology sector. Most biotech startups reinvest 15 to 25 percent of their revenue back into research, often operating at a loss for a decade or more while advancing therapeutic pipelines through clinical trials. For these firms, a non-refundable credit that only offsets future tax liability is of little immediate use. A refundable credit, however, acts as a direct grant, effectively extending the “runway” for critical scientific milestones.

The Major Research and Development Expenses Tax Credit (§ 58.1-439.12:11)

As companies scale and their research expenditures exceed $5 million annually, they transition from the Standard R&D Credit to the Major R&D Credit. This credit is non-refundable but offers a 10-year carryforward provision, allowing large enterprises and high-growth SMBs to offset significant future tax liabilities as they bring products to market. The credit calculation for the Major R&D Credit is typically volume-based, focused on 10 percent of the difference between current-year expenses and a base amount.

Table 2: Major R&D Credit Specifications

The Major R&D Credit ensures that Virginia remains competitive for large-scale laboratory investments and corporate headquarters. However, the $16 million statewide cap is often reached, leading to a pro rata apportionment that can reduce the effective value of the credit for individual taxpayers.

3. The Current Legislative Crisis: The 2025 Sunset

A defining characteristic of the current Virginia R&D framework is its instability. Both the Standard and Major R&D credits were set to expire for taxable years beginning on or after January 1, 2025. During the 2025 Regular Session of the Virginia General Assembly, House Bill 1969 (HB 1969) was introduced to extend these sunset dates. Despite broad support from the innovation and business communities, the bill failed to pass from a conference committee in February 2025. As a result, Virginia currently has no active state R&D tax credit for the current taxable year, placing the Commonwealth at a severe disadvantage compared to neighboring states with permanent or long-term incentives.

4. The Policy Issue: Categorical Exclusions in Bio-Medical Research

Embedded within both § 58.1-439.12:08 and § 58.1-439.12:11 is a provision that categorically excludes certain types of biomedical research from eligibility. Specifically, the statutes state that no tax credit shall be allowed if the research and development expenses are paid for or incurred by a taxpayer for research conducted in the Commonwealth on “human cells or tissue derived from induced abortions or from stem cells obtained from human embryos”. While the law clarifies that this exclusion does not apply to non-embryonic stem cells (such as adult stem cells or induced pluripotent stem cells), the administrative and scientific reality for biotechnology SMBs is far more complex than this distinction suggests.

The Origins and Intent of the Exclusion

The bio-medical research exclusion was introduced in 2011 via House Bill 1447 (HB 1447), which established the modern R&D tax credit framework. The legislative intent was to ensure that state-funded tax incentives were not used to promote research that many policymakers and constituents viewed as ethically controversial. To enforce this, the Department of Taxation was tasked with developing guidelines and mandatory reporting requirements. This resulted in Question 8 on the standard Form RDC application: “Do you conduct research and development in Virginia on human cells or tissue derived from induced abortions or from stem cells obtained from human embryos?”.

A “Yes” response to this question triggers a series of consequences. Under the Department’s guidelines, if a taxpayer conducts any such research, they are ineligible for the credit on those specific expenses. Furthermore, if the taxpayer conducts such research, any other qualified research expenses they claim are converted from refundable to non-refundable credits. For a pre-revenue startup, this conversion is effectively a total denial of the incentive’s value.

The Scientific Barrier: Why the Exclusion Matters Today

In the years since the 2011 exclusion was enacted, the field of biotechnology has undergone a paradigm shift. Regenerative medicine, which focuses on restoring or replacing cell, tissue, and organ functions, has emerged as a cornerstone of modern healthcare. At the heart of this innovation are stem cells, which possess the unique ability to self-renew and differentiate into specialized cell types.

Human embryonic stem cells (hESCs) are pluripotent, meaning they can become any of the 200+ cell types in the human body. While induced pluripotent stem cells (iPSCs)—which are derived from adult cells and reprogrammed—have provided a valuable alternative that circumvents some ethical concerns, hESCs remain the “gold standard” for benchmarking and validation. Many cutting-edge research projects, particularly those involving complex organoids or bio-printing of functional tissue, require the use of hESCs as controls or foundational materials.

By excluding hESC research, Virginia’s tax policy creates a “compliance trap” for biotech startups. A company may be 90% focused on iPSC-based therapies but use a small amount of hESC-derived material for comparative analysis. Under current law, the presence of that small hESC component can disqualify the entire project’s eligibility for a refundable credit, forcing the startup to either abandon the scientifically superior methodology or forego the financial lifeblood of the tax credit.

The Administrative Burden on SMBs

For small to medium-sized businesses, the burden of proving that no “prohibited” cells were used in a multi-stage R&D process is immense. R&D in the life sciences is rarely a linear path; it involves the integration of various cell lines, reagents, and equipment. The Department of Taxation requires “rigorous documentation and substantiation” for R&D claims, including time logs, receipts, and a clear narrative of the research purpose.

When the bio-medical exclusion is introduced, an SMB must not only satisfy the federal “Four-Part Test” for R&D but also maintain a secondary accounting system to prove the “ethical provenance” of every biological sample used in the lab. For a startup with fewer than 50 employees, the cost of this administrative compliance can often outweigh the $45,000 to $60,000 maximum credit available under the Standard R&D program.

5. The Economic Context: Virginia’s Bioscience Ecosystem and the Return on Investment

To evaluate the impact of the bio-medical exclusion, one must first understand the immense value that the bioscience industry brings to Virginia. The Commonwealth is home to over 2,000 bioscience establishments, employing more than 24,000 people with an average annual wage exceeding $86,000. This sector is a primary driver of Virginia’s knowledge economy, particularly through its research-heavy institutions.

The Role of Higher Education as an Economic Engine

Virginia’s research universities are the primary source of biotech innovation and startup spin-offs. The University of Virginia (UVA) and Virginia Tech (VT) serve as “anchor institutions” for regional bioscience clusters.

Table 3: Economic Impact of Virginia Academic Research Centers

The research conducted at these universities is the foundation for startups like HemoShear Therapeutics in Charlottesville, which uses man-made vascular cells to recreate human liver diseases for drug discovery, and Tiny Cargo Co. in Roanoke, which is scaling exosome extraction for drug delivery. These companies represent the “high-multiplier” jobs that state leaders prioritize. Every “star scientist” attracted to a state by its research environment increases the number of related jobs in the sector by an average of 31 percent.

The Multiplier Effect of R&D Tax Credits

Research and development tax credits are not merely a “tax break” for corporations; they are a catalytic investment. Studies on state-level biotech incentives found that adopting these subsidies raised the number of star scientists by 15 percent and sector employment by an average of 16 to 18 percent. Furthermore, the benefits extend into local “non-traded” industries such as construction, retail, and real estate as biotech clusters take off.

In Virginia, the R&D credit has been instrumental in supporting the “Building Better Medicine” initiative, which leverages a $52.9 million federal Build Back Better grant to expand the domestic supply chain for active pharmaceutical ingredients (APIs). For the startups within this supply chain, the state R&D tax credit provides the capital needed to transition from the university lab to commercial manufacturing.

6. Competitive Analysis: How Virginia Compares to Regional Rivals

Virginia’s biotechnology ambitions do not exist in a vacuum. The Commonwealth is in direct competition with Maryland, Massachusetts, and North Carolina for the same pool of venture capital and scientific talent. When Virginia maintains restrictive and ethically-bounded tax policies while its neighbors offer flexible, industry-agnostic incentives, it creates a “competitive gap” that encourages startups to relocate.

Maryland: The BioHealth Capital Region

Maryland has positioned itself as a global leader in biotechnology through its Biotechnology Investment Incentive Tax Credit (BIITC). This program offers a refundable state income tax credit equal to 33 percent to 50 percent of an eligible investment in a Qualified Maryland Biotechnology Company (QMBC).

• Refundability: The credit is fully refundable if the investor has no Maryland tax liability, making it highly attractive for pre-revenue firms.
• Targeted Support: Enhanced credits are available for companies located in “RISE Zones” or federal Opportunity Zones, with credit rates reaching as high as 75 percent.
• Inclusivity: Maryland’s program focuses on the technical definition of biotechnology—technologies that “comprise, interact with, or analyze biological material”—without specific statutory bans on ESC-related research in its tax incentive language.

Massachusetts: The Life Sciences Leader

Massachusetts offers the most robust suite of incentives in the nation through the Massachusetts Life Sciences Center (MLSC). This program provides up to $40 million annually in tax incentives across nine different categories, including refundable R&D credits.

• Flexibility: Companies can allocate their awarded credits across different needs, such as capital equipment (ITC), jobs tax credits, or FDA user fee offsets.
• Job Creation focus: Incentives are tied to multi-year job creation and retention, with base awards of $18,000 per new job, increasing to $33,000 for small companies in remote areas.
• Scale: Since its inception, the MLSC has awarded $382 million in tax incentives, supporting the creation of more than 20,700 jobs.

The North Carolina Model

North Carolina utilizes a combination of R&D tax credits and specialized grants to attract biomanufacturing. Its R&D tax credit provides up to 13.5 cents for every qualified dollar, which can be carried forward for 20 years. North Carolina’s strategy focuses on its massive manufacturing workforce (nearly half a million workers) and the synergy between large multinational firms and small startups.

Table 4: Regional Life Sciences Tax Incentive Comparison

The data illustrates that Virginia’s credit rates are significantly lower than Maryland’s, and its program lacks the flexibility and scale of the Massachusetts model. Most importantly, Virginia is the only state in this group with an explicit, ethically-based statutory exclusion that actively disqualifies specific biomedical research categories.

7. Solution 1: Ethical Alignment with the NIH Registry (The “Safe Harbor” Model)

The first practical solution to resolve the bio-medical research barrier while respecting the ethical intent of the General Assembly is to replace the blanket exclusion with a “Safe Harbor” provision aligned with the National Institutes of Health (NIH) Human Embryonic Stem Cell Registry. This approach moves away from a categorical ban and toward a standards-based model that is already the norm for federal research funding.

The Mechanism of the Solution

The NIH maintains a registry of human embryonic stem cell (hESC) lines that are eligible for federal research funding. These lines have been vetted to ensure they were derived from embryos that were created for reproductive purposes and were no longer needed for those purposes, with the full informed consent of the donors and no financial inducement.

The Virginia Legislature could amend § 58.1-439.12:08(M) and § 58.1-439.12:11(I) to state:

Benefits for SMBs and the State

By adopting the NIH Registry as the standard for tax credit eligibility, Virginia would achieve three primary goals:

• Scientific Realism: Startups would no longer be penalized for using the “gold standard” cell lines required for FDA validation and benchmarking.
• Administrative Simplicity: Taxpayers would simply need to provide the NIH Registry ID for the cell lines used in their research. This eliminates the need for complex “ethical tracing” and reduces the audit risk for SMBs.
• Ethical Consistency: The Commonwealth would still prohibit the use of tax dollars for research involving tissue from induced abortions (consistent with current NIH policy) while allowing the use of established, ethically-donated stem cell lines that are already used in federal research.

Safeguards Against Fraud and Wastage

To ensure that this expanded eligibility is not abused, the Department of Taxation can implement the following controls:

• Certification Requirement: Applicants must attach a certification from their Institutional Review Board (IRB) or Institutional Biosafety Committee (IBC) confirming that all hESC research conducted during the taxable year utilized Registry-listed lines.
• Attestation on Form RDC: Form RDC can be updated to include a specific attestation: “I certify that all human embryonic stem cell research for which credits are claimed was conducted on cell lines listed on the NIH Human Embryonic Stem Cell Registry as of the date the research was performed”.
• Third-Party Verification: For credits exceeding a certain threshold (e.g., $100,000), the state could require a verification statement from an independent scientific auditor, ensuring the funds were used for the specific purposes described in the application.

8. Solution 2: The “Regenerative Medicine Catalyst” Enhanced Refundable Tier

The second solution addresses the financial barrier by creating a specialized, enhanced tier of the R&D tax credit specifically for high-impact life science sectors, including regenerative medicine and cell therapy. This model is inspired by the Massachusetts “Certified Life Sciences Company” program and is designed to attract the most capital-intensive startups to Virginia.

The Mechanism of the Solution

The Virginia General Assembly should establish a “Life Science Catalyst” (LSC) certification program within the Department of Taxation and the Virginia Economic Development Partnership (VEDP). SMBs that meet certain criteria—such as high R&D intensity, significant job creation potential, and a focus on unmet medical needs—could apply for LSC status.

Once certified, an LSC-SMB would be eligible for:

• An Enhanced Credit Rate: 25 percent of the first $500,000 in Virginia QREs (compared to the current 15/20 percent of $300,000).
• Full Refundability for Mid-Sized Firms: Currently, once a firm’s expenses exceed $5 million, they lose refundability by moving to the Major R&D Credit. The LSC tier would allow certified life science companies to maintain refundability up to $10 million in expenses, providing critical liquidity during the costly clinical trial phase.
• Sales and Use Tax Exemption: Automatic eligibility for sales tax exemptions on all laboratory equipment and materials used in regenerative medicine research, mirroring the benefits offered in North Carolina and Massachusetts.

Implementation for the Benefit of SMBs

This solution directly addresses the “Valley of Death” in biotech funding—the period after initial venture capital is raised but before a product is approved for sale. By offering a higher credit rate and extending refundability, Virginia makes itself the most financially attractive state in the Mid-Atlantic for regenerative medicine.

The application process would be integrated with the existing Virginia Bio-Connect initiative, leveraging the regional “BioHubs” to help companies navigate the certification process. This provides SMBs with a network of mentors and resources, increasing their chances of technical and commercial success.

Safeguards Against Fraud and Wastage

The LSC tier would be a “performance-based” incentive, utilizing the following safeguards:

• Pre-Certification Audit: Before receiving LSC status, the VEDP would conduct a detailed review of the company’s financial records, employment levels, and scientific plan to ensure the company has a “physical footprint” in Virginia.
• Annual Reporting and Clawbacks: Companies must file annual reports detailing their progress toward hiring and investment commitments. If a company fails to meet these targets or relocates out of state, the Commonwealth would have the statutory authority to “claw back” the value of the credits.
• Defined Expenditure Categories: The enhanced credit would only apply to “Qualified Research Expenses” as defined by IRC § 41(b), which includes wages for researchers, supplies, and 65% of contract research payments. This prevents the credits from being used for general administrative overhead or executive bonuses.

9. Implementation Strategy: Ensuring Transparency and Scientific Integrity

Modernizing Virginia’s R&D tax credit requires a sophisticated approach to administration. The Department of Taxation must bridge the gap between tax accounting and biological science, a challenge that can be met through inter-agency collaboration and clear, evidence-based guidelines.

The “Four-Part Test” in the Biological Context

To prevent waste and ensure that credits are only awarded for genuine innovation, the Commonwealth should strictly adhere to the federal “Four-Part Test” while providing specific biological interpretations.

• Permitted Purpose: The research must be intended to create a new or improved “business component”. In biotechnology, this means a drug, a diagnostic tool, or a proprietary tissue model (like HemoShear’s vascular systems).
• Technological in Nature: The research must rely on the biological or physical sciences. This excludes market research, efficiency surveys, or social science studies.
• Elimination of Uncertainty: The company must prove that they faced technological uncertainty regarding the “capability, method, or design” of the therapeutic product.
• Process of Experimentation: The taxpayer must evaluate one or more alternatives through a systematic trial-and-error approach, such as modeling, simulation, or clinical testing.

By requiring SMBs to provide a “Clear Narrative” explaining how their biological research meets these four tests, the Department of Taxation can filter out fraudulent or non-qualifying claims before they are ever processed.

Integrated Inter-Agency Oversight

The Department of Taxation is primarily an auditing body, not a scientific review board. To implement the bio-medical policy changes effectively, the Commonwealth should establish a “Life Science Tax Advisory Committee” (LSTAC) composed of representatives from:

• The Virginia Department of Health (VDH): To verify the ethical standards and Registry status of cell lines.
• The Virginia Biotechnology Association (Virginia Bio): To provide industry perspective on research trends.
• State Research Universities: To provide independent scientific validation of the “experimentation” claims.

This committee would meet quarterly to review large-scale or complex applications, ensuring that the Commonwealth’s investments are flowing toward scientifically sound and ethically compliant research.

10. Cost Analysis: Initial Outlay and Future Economic Dividends

A primary concern for the Virginia General Assembly is the fiscal impact of expanding R&D tax credits. However, when framed correctly, the cost of these incentives is a fraction of the tax revenue and economic output they generate.

The Direct Fiscal Impact

In FY 2024, the total cap for Virginia’s R&D credits (Standard and Major) was approximately $31.77 million. Expanding the Standard credit to include Registry-listed ESC research and creating the enhanced “Life Science Catalyst” tier would likely increase this demand.

Table 5: Projected Fiscal Outlay for LSC Implementation

While an additional $20 million in annual credit availability represents an “initial outlay,” it must be viewed in the context of Virginia’s $455 million in annual tax revenue generated by a single research university (UVA).

The Long-Term Return on Investment (ROI)

The return on biotech incentives is realized through three primary channels:

• Direct Tax Revenue: Every high-wage scientist hired by an SMB (average wage $86,000+) pays state income tax. A cluster of 1,000 new scientists would generate approximately $4 million to $5 million in direct state income tax revenue annually, not including payroll taxes.
• The Manufacturing Multiplier: As startups mature, they build manufacturing plants. AstraZeneca’s $4.5 billion plant in Albemarle County and Merck’s $3 billion facility in the Shenandoah Valley are the direct result of a decade of R&D investment in the region. These facilities generate thousands of construction jobs and millions in local property and machinery-and-tools taxes.
• Federal Grant Attractiveness: State R&D incentives make Virginia companies more competitive for federal SBIR/STTR grants and NIH funding. Virginia already receives over $500 million in annual NIH funding; a robust state tax credit acts as a “multiplier” for these federal dollars by providing the local match often required for commercialization.

Applying the UVA ROI model ($35 in impact for every $1 invested), a $20 million increase in R&D credit availability could theoretically catalyze $700 million in total economic impact for the Commonwealth.

11. Importance of the Policy Change: The High Stakes of Innovation

The modernization of Virginia’s R&D tax credit is not merely a fiscal adjustment; it is a vital step toward securing the Commonwealth’s future in the global economy.

Attracting “Star Scientists” and Institutional Strength

The presence of “star scientists”—those at the top of their fields in patenting and discovery—is the single most important factor in the growth of a biotech cluster. These individuals attract venture capital, high-quality students, and secondary firms. However, star scientists are highly mobile. If Virginia maintains an ethically restrictive tax code that prohibits their work on Registry-listed cell lines, they will simply take their research to Maryland or Massachusetts.

The Consequences of Inaction: “Innovation Stagnation”

If the Virginia General Assembly does not reinstate and modernize the R&D credits:

• Talent Flight: The 97 university students and postdocs recently hired by Virginia life science companies through the Bio-Connect program will find their roles at risk as startups lose their primary cash flow mechanism.
• Capital Flight: Venture capital firms, which invested $26 billion in bioscience in 2024, will avoid Virginia due to the “policy volatility” represented by the 2025 sunset and the unaddressed research exclusions.
• Degradation of Public-Private Partnerships: Virginia’s research universities rely on tax-incentivized startups to commercialize their intellectual property. Without these startups, world-class discoveries made at UVA and Virginia Tech will sit on a shelf rather than becoming life-saving therapies.

12. Conclusion: A Roadmap for the 2026 General Assembly

The expiration of Virginia’s R&D tax credits at the end of 2024 provides a unique opportunity for the 2026 General Assembly to not just reinstate the status quo, but to build a more competitive, scientifically-aligned framework. By adopting a standards-based approach to bio-medical research and creating a dedicated tier for life science SMBs, Virginia can reconcile its ethical priorities with the demands of modern science.

The Commonwealth is currently losing its competitive edge to regional rivals that offer greater financial support and less regulatory friction. To reclaim its position, Virginia must prioritize “predictable cash” for startups, eliminate administrative “compliance traps,” and treat its R&D tax credit as the high-yield investment that it is. The long-term benefits—high-wage jobs, a robust tax base, and the development of therapies that cure chronic diseases—far outweigh the initial fiscal outlay and the administrative challenge of reform.

Obras citadas

1. The U.S. Bioscience Industry: – Biotechnology Innovation Organization | BIO, fecha de acceso: marzo 18, 2026, https://www.bio.org/sites/default/files/2025-12/BIO%20CSBA_2025%20Best%20Practices%20Report.pdf
2. New Report Highlights State and Regional Strategies Powering U.S. Biotech | VirginiaBio, fecha de acceso: marzo 18, 2026, https://www.vabio.org/new-report-highlights-state-and-regional-strategies-powering-u-s-biotech/
3. Alliance for Building Better Medicine | U.S. Economic Development Administration, fecha de acceso: marzo 18, 2026, https://www.eda.gov/funding/programs/american-rescue-plan/build-back-better/finalists/virginia-biotechnology-research-partnership-authority
4. Virginia Tech generates $4.7 billion in economic impact across Virginia, new report shows, fecha de acceso: marzo 18, 2026, https://news.vt.edu/articles/2026/02/cm-economicimpact-2026.html
5. GO Virginia Regional Council 4 Annual Report July 1, 2024, to June 30, 2025, fecha de acceso: marzo 18, 2026, https://www.dhcd.virginia.gov/sites/default/files/DocX/gova/region-four/gova-r4-annual-report.pdf
6. VIRGINIA: Big Biotech Things Come In Big and Tiny Packages – Site Selection Magazine, fecha de acceso: marzo 18, 2026, https://siteselection.com/virginia-big-biotech-things-come-in-big-and-tiny-packages/
7. SB1048 – 2023 Regular Session – LIS, fecha de acceso: marzo 18, 2026, https://lis.virginia.gov/bill-details/20231/SB1048/text/SB1048
8. § 58.1-439.12:08. Research and development expenses tax credit – Virginia Law, fecha de acceso: marzo 18, 2026, https://law.lis.virginia.gov/vacode/title58.1/chapter3/section58.1-439.12:08/
9. § 58.1-439.12:11. Major research and development expenses tax credit – Virginia Law, fecha de acceso: marzo 18, 2026, https://law.lis.virginia.gov/vacode/title58.1/chapter3/section58.1-439.12:11/
10. Virginia R&D Tax Credit: 2025 Sunset Implications and 2026 Outlook | Cherry Bekaert, fecha de acceso: marzo 18, 2026, https://www.cbh.com/insights/articles/virginia-rd-tax-credit-changes-impact-on-businesses/
11. Virginia R&D Tax Credits – Strike Tax Advisory, fecha de acceso: marzo 18, 2026, https://www.striketax.com/state-rd-credits/virginia-r-d-tax-credits
12. Virginia R&D Tax Credit Explained for Businesses – Swanson Reed, fecha de acceso: marzo 18, 2026, https://www.swansonreed.com/research-tax-credit/virginia/
13. Major tax wins for startups: R&D relief and hiring credits explained – NextCorps, fecha de acceso: marzo 18, 2026, https://nextcorps.org/major-tax-wins-for-startups-rd-relief-and-hiring-credits-explained/
14. How State R&D Incentives Influence Biotech Expansion Decisions in the U.S. – GlobalDeal, fecha de acceso: marzo 18, 2026, https://globaldeal.io/blog/incentives-influence-biotech-expansion-decisions
15. State R&D Tax Credits for Biotech: The Hidden Opportunity Most Life Sciences Companies Miss – Boast, fecha de acceso: marzo 18, 2026, https://www.boast.ai/en-us/blog/r-and-d/state-rd-tax-credits-for-biotech-the-hidden-opportunity-most-life-sciences-companies-miss
16. Bill Tracking – 2024 session > Legislation – legacy LIS, fecha de acceso: marzo 18, 2026, https://legacylis.virginia.gov/cgi-bin/legp604.exe?241+ful+HB1518E+hil
17. Virginia-2011-HB1447-Conference Sub – LegiScan, fecha de acceso: marzo 18, 2026, https://legiscan.com/VA/text/HB1447/id/200700/Virginia-2011-HB1447-Conference_Sub.html
18. Research and Development Expenses Tax Credit … – Virginia Tax, fecha de acceso: marzo 18, 2026, https://www.tax.virginia.gov/sites/default/files/inline-files/Research_and_Development_Expenses_Tax_Credit_Guidelines.pdf
19. Form RDC – TaxFormFinder, fecha de acceso: marzo 18, 2026, https://www.taxformfinder.org/forms/2011/2011-virginia-form-rdc.pdf
20. 2024 Form RDC – Application for Research and Development Expenses Tax Credit – Virginia Tax, fecha de acceso: marzo 18, 2026, https://www.tax.virginia.gov/sites/default/files/taxforms/credits-subtractions-and-deductions/2024/rdc-2024.pdf
21. Unlocking the Healing Potential: How Stem Cells Are Shaping Regenerative Medicine and Wound Care – Human BioSciences, fecha de acceso: marzo 18, 2026, https://humanbiosciences.com/woundcareblog/unlocking-the-healing-potential-how-stem-cells-are-shaping-regenerative-medicine-and-wound-care/
22. GAO-23-105430, TECHNOLOGY ASSESSMENT: Regenerative Medicine, Therapeutic Applications, Challenges, and Policy Options, fecha de acceso: marzo 18, 2026, https://www.gao.gov/assets/gao-23-105430.pdf
23. Immortal: An oral history of stem cell discovery – Morgridge Institute for Research, fecha de acceso: marzo 18, 2026, https://morgridge.org/feature/immortal/
24. Ayla Annac | Ellevate, fecha de acceso: marzo 18, 2026, https://www.ellevatenetwork.com/member-spotlights/196
25. The IPSI Transactions on – Internet Research, fecha de acceso: marzo 18, 2026, https://ipsitransactions.org/journals/papers/tir/2025jul/fullPaper.pdf
26. 18th edition – 2025 tech trends report – Future Today Strategy Group, fecha de acceso: marzo 18, 2026, https://ftsg.com/wp-content/uploads/2025/03/FTSG_2025_TR_FINAL_LINKED.pdf
27. R&D Tax Credit | Advisory and Audit Services – Anchin, fecha de acceso: marzo 18, 2026, https://www.anchin.com/services/research-development-tax-credits/rd-audit-defense/
28. How to Handle an R&D Tax Credit Audit – FI Group, fecha de acceso: marzo 18, 2026, https://www.fi-group.us/how-to-handle-an-rd-tax-credit-audit
29. R&D tax credits guide for CPAs – ADP, fecha de acceso: marzo 18, 2026, https://www.adp.com/resources/articles-and-insights/articles/r/r-and-d-tax-credit-guide-for-cpas.aspx
30. Practical Documentation of QRAs for the R&D Tax Credit – The Tax Adviser, fecha de acceso: marzo 18, 2026, https://www.thetaxadviser.com/issues/2016/jul/practical-documentation-of-qras-for-r-and-d-tax-credit/
31. Bio Tax Credit | Maryland Department of Commerce, fecha de acceso: marzo 18, 2026, https://commerce.maryland.gov/fund/programs-for-businesses/bio-tax-credit
32. New BIO Report Highlights Virginia’s Bioscience Industry Increases Jobs, NIH Awards and More | VirginiaBio, fecha de acceso: marzo 18, 2026, https://www.vabio.org/new-bio-report-highlights-virginias-bioscience-industry-increases-jobs-nih-awards-and-more/
33. UVA Economic Impact – The University of Virginia, fecha de acceso: marzo 18, 2026, https://at.virginia.edu/EconomicImpact
34. Virginia Bio-Connect – The Success of Virginia’s First Statewide Collaborative Life Sciences Initiative | VirginiaBio, fecha de acceso: marzo 18, 2026, https://www.vabio.org/virginia-bio-connect-the-success-of-virginias-first-statewide-collaborative-life-sciences-initiative/
35. Life Sciences Industry On Uptick In Virginia, fecha de acceso: marzo 18, 2026, https://www.lifescienceleader.com/doc/life-sciences-industry-on-uptick-in-virginia-0001
36. Build out: Three companies now calling the old Martha Jefferson site home, fecha de acceso: marzo 18, 2026, https://c-ville.com/build-out-three-companies-now-calling-the-old-martha-jefferson-site-home/
37. State Biotech Incentives Attract Jobs, But Do Less for Established Firms | SSTI, fecha de acceso: marzo 18, 2026, https://ssti.org/blog/state-biotech-incentives-attract-jobs-do-less-established-firms
38. Maryland Tax – General Code Section 10-725 (2024) – Biotechnology Investment Incentive Tax Credit – Justia Law, fecha de acceso: marzo 18, 2026, https://law.justia.com/codes/maryland/tax-general/title-10/subtitle-7/section-10-725/
39. Programs – State Business Incentives Database, fecha de acceso: marzo 18, 2026, https://www.stateincentives.org/programs/report.asp?ProgramID=2122
40. Maryland – Research Credits–Biotechnology Investment – Income Taxes, Personal – Explanations – CCH AnswerConnect | Wolters Kluwer, fecha de acceso: marzo 18, 2026, https://answerconnect.cch.com/document/jmd0109013e2c85b14f0f/state/explanations/maryland/research-credits-biotechnology-investment
41. Life Sciences Tax Incentive Program – Massachusetts Life Sciences …, fecha de acceso: marzo 18, 2026, https://www.masslifesciences.com/wp-content/uploads/MLSC-2025-Tax-Incentive-Solicitation.pdf
42. Massachusetts Life Sciences Center Launches 17th Round of Tax Incentive Program, fecha de acceso: marzo 18, 2026, https://www.masslifesciences.com/massachusetts-life-sciences-center-launches-17th-round-of-tax-incentive-program/
43. Tax Incentive – Massachusetts Life Sciences Center, fecha de acceso: marzo 18, 2026, https://www.masslifesciences.com/programs/tax-incentive/
44. Massachusetts Life Sciences Companies Tax Incentives Application Due March 31, 2026 – Moss Adams, fecha de acceso: marzo 18, 2026, https://www.mossadams.com/articles/2026/02/apply-for-life-sciences-tax-incentives-in-ma
45. MLSC Tax Incentives Program: Eligibility, Calculation & More | Cherry Bekaert, fecha de acceso: marzo 18, 2026, https://www.cbh.com/insights/articles/2025-mlsc-tax-incentives-eligibility-calculation-more/
46. North Carolina R&D Tax Credit Case Study – KBKG, fecha de acceso: marzo 18, 2026, https://www.kbkg.com/rd-tax-credit-case-study/north-carolina
47. The R&D Tax Credit Aspects of Doing Business in North Carolina, fecha de acceso: marzo 18, 2026, https://www.rdtaxsavers.com/articles/North-Carolina
48. NIH Prohibits Use of Federal Funds for Research Involving Human Fetal Tissue from Elective Abortions | Ropes & Gray LLP – JD Supra, fecha de acceso: marzo 18, 2026, https://www.jdsupra.com/legalnews/nih-prohibits-use-of-federal-funds-for-4970916/
49. HHS Bars Research Using Human Fetal Tissue from Elective Abortions, fecha de acceso: marzo 18, 2026, https://www.hhs.gov/press-room/hhs-bars-research-using-human-fetal-tissue-from-elective-abortions.html
50. Regions | VirginiaBio, fecha de acceso: marzo 18, 2026, https://www.vabio.org/membership/regions/
51. Audit techniques guide: Credit for Increasing Research Activities (i.e. Research Tax Credit) IRC § 41* – Qualified research activities | Internal Revenue Service, fecha de acceso: marzo 18, 2026, https://www.irs.gov/businesses/audit-techniques-guide-credit-for-increasing-research-activities-ie-research-tax-credit-irc-ss-41-qualified-research-activities